La chaîne d'options affiche les données clés des options sur actions de Galmed Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Galmed Pharmaceuticals..

Galmed Pharmaceuticals (NASDAQ:GLMD) Stock, Chaîne d'Options

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals Ltd

Small Cap

Press Releases

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

News

Emerging Growth Leaders: – INEO, PLUG, HIT, GLMD, OMEX, More Stocks Inside – Health, Energy, Mining, and Defense Making Headlines

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models

Earnings

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GLMD

INEO

OMEX

PLUG

PNPNF

PRSO

TSXV:PNPN

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Alzamend Neuro

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cosciens Biopharma

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

enGene Holdings

Ensysce Biosciences

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

Palisade Bio

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

Comments

Galmed Pharmaceuticals

Galmed Pharmaceuticals (GLMD) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL